Sandbox:DN: Difference between revisions
Dima Nimri (talk | contribs) (Blanked the page) |
Dima Nimri (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
==Overview== | |||
Dual antiplatelet therapy (or DAPT) refers to the combination of [[aspirin]] and a P2Y12 receptor antagonist. DAPT is approved for [[SIHD]] and interventions for [[ACS]], such as stent placement following [[PCI]] or [[CABG]]. The duration of treatment with DAPT for each of these categories differs and guidelines for treatment have been updated in the ''2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease''. Much of the studies done on DAPT compared the use of different types of P2Y12 receptor antagonists, the dosage of drugs, as well as the duration of treatment. The current consensus is that the use of DAPT is associated with decreased risk of [[stent thrombosis]], [[MI]] and [[stroke]]. However, the benefits of treatment should be weighed against the increased risk of major bleeding in certain patient populations. | |||
Revision as of 15:40, 4 November 2016
Overview
Dual antiplatelet therapy (or DAPT) refers to the combination of aspirin and a P2Y12 receptor antagonist. DAPT is approved for SIHD and interventions for ACS, such as stent placement following PCI or CABG. The duration of treatment with DAPT for each of these categories differs and guidelines for treatment have been updated in the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. Much of the studies done on DAPT compared the use of different types of P2Y12 receptor antagonists, the dosage of drugs, as well as the duration of treatment. The current consensus is that the use of DAPT is associated with decreased risk of stent thrombosis, MI and stroke. However, the benefits of treatment should be weighed against the increased risk of major bleeding in certain patient populations.